Exhibit 99.1

 

LOGO

 

FOR IMMEDIATE RELEASE

 

Contact:    
Adolor Corporation   Sam Brown, Inc. (media)
Michael R. Dougherty   Nicole McLane (610) 889-9788
Senior Vice President, COO and CFO   Stern Investor Relations (investors)
(484) 595-1500   Lilian Stern (212) 362-1200

 

ADOLOR CORPORATION REPORTS

 

YEAR END 2004 FINANCIAL RESULTS

 

EXTON, Pa., March 1, 2005

— Adolor Corporation (NASDAQ: ADLR) today reported financial results for the year and fourth quarter ended December 31, 2004.

 

For the twelve months ended December 31, 2004, the Company reported a net loss of $43.6 million or $1.12 per basic and diluted share, compared to a net loss of $51.2 million or $1.57 per basic and diluted share for the same period in 2003. For the three months ended December 31, 2004, the Company reported a net loss of $11.6 million or $0.30 per basic and diluted share, compared to a net loss of $14.5 million or $0.41 per basic and diluted share in the three months ended December 31, 2003.

 

“In 2004, we made significant progress towards our goal of becoming a fully integrated biopharmaceutical company,” stated Bruce A. Peacock, president and chief executive officer of Adolor. “We were proud to submit our first NDA to the Food and Drug Administration in June for our lead product, Entereg (TM), in the management of postoperative ileus. The FDA accepted the Entereg NDA for review in September, which triggered the receipt of a $10.0 million milestone payment from GlaxoSmithKline.”

 

“Further, GSK advanced Entereg’s development in additional indications and we are awaiting data from Phase 2 studies in chronic OBD and chronic constipation,” continued Mr. Peacock. “Our R&D group continued to make progress in the sterile lidocaine patch and analgesic discovery research programs. We ended 2004 with approximately $162.3 million in cash and investments.”

 

Contract revenues for the twelve months ended December 31, 2004 were $25.5 million compared to $20.7 million in the same period in 2003. This increase is primarily due to the recognition of $10.0 million in milestone revenue received from Glaxo Group Limited (“Glaxo”) in 2004, partially offset by a reduction in cost reimbursement revenues relating to a decrease in expenses incurred by us which are reimbursable by Glaxo under the collaboration agreement. Contract revenues for the three months ended December 31, 2004 were $4.4 million, compared to $4.1 million in the same period of 2003.


The following information was filed by Adolor Corp (ADLR) on Tuesday, March 1, 2005 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Adolor Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adolor Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account